The development of targeted therapies for ER/PR-positive and HER2-overexpressing tumors has improved the clinical outcome of patients, whereas women that are diagnosed with TNBC remain the group of breast cancer patients with the poorest prognosis, due to the absence of molecular targets and the consequent limitation of treatment options. Here, ERBB2 is linked to breast cancer.